Please use this identifier to cite or link to this item:
https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3371
Journal Title: | A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial |
Authors: | Davidson, A. Veillard, A. S. Tognela, A. Chan, M. M. Hughes, B. G. Boyer, M. Briscoe, K. Begbie, S. Abdi, E. Crombie, C. Long, J. Boyce, A. Lewis, C. R. Varma, S. Broad, A. Muljadi, N. Chinchen, S. Espinoza, D. Coskinas, X. Pavlakis, N. Millward, M. Stockler, M. R. Australasian Lung cancer Trials, Group Australasian Lung cancer Trials Group, Altg |
SWH Author: | Davidson, Adee |
Keywords: | Adult Aged 80 and Over Antineoplastic Combined Chemotherapy Protocols Australia Carcinoma Female Follow-Up Studies Humans Lung Neoplasms Male Middle Aged Nitroglycerin Chemotherapy Lung Cancer Phase 3 Clinical Trial |
Issue Date: | 2015 |
Date Accessioned: | 2023-03-17T04:56:46Z |
Date Available: | 2023-03-17T04:56:46Z |
Accession Number: | 26347110 |
Url: | https://www.ncbi.nlm.nih.gov/pubmed/26347110 |
Description Affiliation: | Department of Medical Oncology, Fiona Stanley Hospital, Perth andrew.davidson@health.wa.gov.au. NHMRC Clinical Trials Centre, University of Sydney, Sydney. Department of Medical Oncology, The Prince Charles Hospital, Brisbane School of Medicine, University of Queensland, Brisbane. Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown. Department of Medical Oncology, Coffs Harbour Health Campus, Coffs Harbour. Department of Medical Oncology, Port Macquarie Base Hospital, Port Macquarie. Department of Medical Oncology, The Tweed Hospital, Tweed Heads School of Medicine & Dentistry, Griffith University, Southport. Department of Medical Oncology, Nepean Cancer Care Centre, Kingswood. Department of Medical Oncology, Nambour General Hospital, Nambour. Department of Medical Oncology, Lismore Base Hospital, Lismore. Prince of Wales Hospital Clinical School, University of New South Wales, Randwick. Department of Medical Oncology, The Townsville Hospital, Townsville. Department of Medical Oncology, Geelong Hospital, Geelong. Department of Medical Oncology, Royal North Shore Hospital, St Leonards. Department of Medical Oncology, Sir Charles Gardiner Hospital, Nedlands School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia. |
Format Startpage: | 2280-6 |
Source Volume: | 26 |
Issue Number: | 11 |
Database: | Medline |
Notes: | (ALTG) eng Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England 2015/09/09 Ann Oncol. 2015 Nov;26(11):2280-6. doi: 10.1093/annonc/mdv373. Epub 2015 Sep 7. |
DOI: | 10.1093/annonc/mdv373 |
Date: | Nov NLM |
Abstract: | BACKGROUND: We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. PATIENTS AND METHODS: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. RESULTS: Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS [median 5.0 versus 4.8 months, hazard ratio (HR) = 1.07, 95% confidence interval (CI) 0.86-1.32, P = 0.55], overall survival (median 11.0 versus 10.3 months, HR = 0.99, 95% CI 0.79-1.24, P = 0.94), or objective tumor response (31% versus 30%, relative risk = 1.03, 95% CI 0.82-1.29, P = 0.81). Headache, hypotension, syncope, diarrhea, dizziness, and anorexia were more frequent in those allocated nitroglycerin. CONCLUSION: The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further. CLINICAL TRIALS NUMBER: Australian New Zealand Clinical Trials Registry Number ACTRN12608000588392. |
URI: | https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3371 |
Journal Title: | Annals of Oncology |
Type: | Journal Article |
Appears in Collections: | SWH Data Contributions |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Annals of Oncology - 2015 - A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer.pdf | 191.5 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.